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During latency, Epstein-Barr virus (EBV) is stably maintained as a circular plasmid that is replicated once
per cell cycle and partitioned at mitosis. Both these processes require a single viral protein, EBV nuclear
antigen 1 (EBNA1), which binds two clusters of cognate binding sites within the latent viral origin, oriP.
EBNA1 is known to associate with cellular metaphase chromosomes through chromosome-binding domains
within its amino terminus, an association that we have determined to be required not only for the partitioning
of oriP plasmids but also for their replication. One of the chromosome-binding domains of EBNA1 associates
with a cellular nucleolar protein, EBP2, and it has been proposed that this interaction underlies that ability
of EBNA1 to bind metaphase chromosomes. Here we demonstrate that EBNA1’s chromosome-binding domains
are AT hooks, a DNA-binding motif found in a family of proteins that bind the scaffold-associated regions on
metaphase chromosomes. Further, we demonstrate that the ability of EBNA1 to stably replicate and partition
oriP plasmids correlates with its AT hook activity and not its association with EBP2. Finally, we examine the
contributions of EBP2 toward the ability of EBNA1 to associate with metaphase chromosomes in human cells,
as well as support the replication and partitioning of oriP plasmids in human cells. Our results indicate that
it is unlikely that EBP2 directly mediates these activities of EBNA1 in human cells.
The latent Epstein-Barr virus (EBV) genome is stably re-
tained in cells extrachromosomally as a circular plasmid. Stable
replication of the EBV genome relies on the latently expressed
viral protein EBV nuclear antigen 1 (EBNA1) binding to both
the family of repeats (FR) within oriP, as well as to cellular
chromosomes. This tethering of viral plasmids to cellular chro-
mosomes is hypothesized to be necessary for their replication
during S phase and partitioning during mitosis.
Homodimers of EBNA1 are bound via a carboxy-terminal
DNA-binding domain (DBD; amino acids [aa] 451 to 640) to
two clusters of binding sites within oriP (60) called the FR and
the dyad symmetry element (DS), whereas the amino terminus
of EBNA1 (aa 1 to 450) is required for an association with
cellular chromosomes (37, 48). During S phase, in concert with
cellular chromosomes, oriP-plasmids are semiconservatively
replicated (1, 2, 11, 47, 61), a process mediated by EBNA1’s
binding at the DS (7). However, the DBD of EBNA1 is by
itself insufficient to recruit the licensed cellular replication
apparatus to DS (28) but requires that the amino terminus of
EBNA1 contain domain(s) that associate with mitotic chromo-
somes (48). We have recently demonstrated that the entire
amino terminus of EBNA1 can be replaced by a cellular pro-
tein that specifically associates with mitotic chromosomes and
that such a fusion supports the stable replication and partition-
ing of oriP plasmids similarly to wild-type EBNA1. In contrast,
a fusion in which the amino terminus associates with inter-
phase chromatin, but not mitotic chromosomes, is unable to
support either the replication or the partitioning of oriP plas-
mids (48). This result strongly suggests that the ability of wild-
type EBNA1 to support both of these processes is mediated by
the ability of the amino terminus of EBNA1 to associate with
mitotic chromosomes.
EBV genomes or oriP plasmids are thought to be partitioned
via a “piggyback” mechanism in which viral episomes are teth-
ered to sister chromatids as they are separated by the cellular
mitotic apparatus (9). This hypothesis is supported by fluores-
cence in situ hybridization analysis which indicates that episo-
mal EBV genomes are associated with sister chromatids (14)
and by indirect immunofluorescence performed by others (37)
and us (48) indicating that EBNA1 is associated in punctate
dots with sister chromatids. Whatever the mechanism of par-
titioning, it is very efficient, with an estimated rate of loss of
between 2 and 6% per cell generation (29, 53), a finding similar
to that observed with centromere-containing plasmids in bud-
ding yeast (22, 30).
EBNA1 associates with mitotic chromosomes through two
regions in its amino terminus that we term domains A (aa 33 to
89) and B (aa 328 to 378). When each of these regions is fused
to green fluorescent protein (GFP), the fusion stains meta-
phase chromosomes as punctate dots (37). These regions share
similarity in sequence, i.e., they both contain repeats of glycine
and arginine (GR repeats), and at least one common biochem-
ical property: DNA linking. When fused to a heterologous
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DBD, the A and B regions link the cognate binding site for the
heterologous DBD into a large macromolecular complex (33,
35). A previous study indicates that EBNA1 derivatives with
either domain A or domain B deleted are equivalent in func-
tion. Similarly, derivatives containing two copies of either do-
main, but none of the other, were also equivalent in function
and are also approximately equivalent in function to wild-type
EBNA1 that contains one copy of each domain (34).
In contrast to these studies, it was reported that EBNA1
with domain B deleted supports the replication of oriP plas-
mids up to 1 week posttransfection in C33A cells but not stably
beyond that time (50). In contrast, derivatives that contained
domain B supported transient and stable replication of oriP
plasmids in the same cells (50). Furthermore, domain B, but
not domain A, associated with a cellular nucleolar protein
(EBP2/p40) (50), and the expression of EBP2 significantly en-
hanced the ability of wild-type EBNA1 to retain ARS/FR plas-
mids in budding yeast (27). The authors of that study have also
found that a fusion between EBP2 and GFP associates with
mitotic chromosomes in human cells (26). On the basis of these
data, it has been proposed that the association of EBNA1 with
mitotic chromosomes is indirect and mediated via EBP2.
In the present study, we have reexamined the mechanism by
which EBNA1 associates with mitotic chromosomes for the
following reasons. We and others have demonstrated that the
cellular protein HMGA1a can functionally replace the amino
terminus of EBNA1 (24, 48). The resulting fusion, HMGA1a-
DBD, supports the replication of oriP plasmids at copy num-
bers equivalent to EBNA1, and oriP plasmids are lost from
cells expressing EBNA1 or HMGA1a-DBD at indistinguisha-
ble rates (48). HMGA1a associates with chromosomes through
a glycine-argine (GR) repeat protein motif termed the AT
hook, which associates with DNA sequences that are rich in
adenine and thymine (4). We noticed that domains A and B
contain such GR-repeats that bear striking similarity to the AT
hooks of cellular AT hook proteins. We have investigated
whether domains A and B can function as AT hooks and have
tested whether AT hook function or an association with EBP2
is required for EBNA1 to associate with cellular chromosomes
and support the replication of oriP plasmids.
Our results indicate that both domains A and B of EBNA1
contain AT hooks and that AT hook activity correlates well
with EBNA1’s ability to associate with cellular chromosomes
and stably replicate oriP plasmids. Further, by utilizing the
observation that only domain B of EBNA1 associates with
EBP2 and by characterizing the localization and activities of a
fusion between EBP2 and the DBD of EBNA1 in human cells,
we demonstrate that EBP2 is unlikely to mediate EBNA1’s
association with mitotic chromosomes. Our results do not elim-
inate the possibility that EBP2 serves as a loader to load
EBNA1 onto mitotic chromosomes, without remaining a com-
ponent of the final bound complex.
MATERIALS AND METHODS
Bacterial strains and plasmid purification. All plasmids were propagated in
the Escherichia coli strains DH5, MC1061/P3, or STBL2 (Invitrogen, Carlsbad,
Calif.). Plasmids used for transfection were purified on isopycnic CsCl gradients
(36).
Replication reporter plasmids. The construction of replication reporter plas-
mid AGP74, containing 20 EBNA1 binding sites in FR has been described
previously (21). This contains a puromycin resistance gene driven by the simian
virus 40 early promoter. A derivative of AGP74 was constructed that contains 30
EBNA1 binding sites in FR (AGP264). To construct this plasmid, a BssHII-
Bsu36I fragment containing 10 EBNA1 binding sites from AGP212 was added to
AGP74 digested with BssHII and Bsu36I.
Generation of EBNA1 derivatives, EBP2 derivatives, and the EBP2-DBD fu-
sion. Domain A of EBNA1 (amino acids 33 to 89) was PCR amplified with
oligonucleotides AGO41 and AGO42. These oligonucleotides contain PflMI and
HindIII recognition sites (underlined) at their 5 ends: AGO41, 5-GGATCCC
CAAGTCCTGGAACCATGTCTGACGAGGGGCCAGG; and AGO42, 5-G
AATTCAAGCTTGGCCTGACTGGCCACCGTGGGTCCCTTTGCAG.
This PCR product was introduced into AGP108 digested with SfiI and HindIII
to create 1A-DBD (AGP117). To generate 2A-DBD (AGP119) and 3A-DBD
(AGP130), the A domain (aa 33 to 89) was PCR amplified with oligonucleotides
AGO17 and AGO43. The product contains the following Bsu36I and PflMI
restriction sites: AGO17, 5-GCTTTGTCATAACAAGGTCC; and AGO43, 5-
GAATTCCCAAGTCCTGGAGTGGACCTCAAAGAAGAGG.
This PCR product was inserted into AGP117 cut with SfiI and Bsu36I to
generate 2A-DBD (AGP119). To generate 3A-DBD (AGP130), the PCR prod-
uct, described above, used to make AGP119 was inserted into AGP119 cut with
SfiI and Bsu36I. It is important to note that, in addition to lacking domain B,
1A-DBD, 2A-DBD, and 3A-DBD also lack aa 386 to 450 of EBNA1. We and
others have previously shown that this region (aa 386 to 450) of EBNA1 is not
required for its function. The coding sequences for 1A-DBD, 2A-DBD, and
3A-DBD were moved into the retroviral expression vector AGP164, a derivative
of pLXSN (AGP171, AGP172, and AGP173, respectively).
Harris Busch and Ben Valdez (Baylor College of Medicine, Houston, Tex.)
kindly provided us with a cDNA clone of EBP2 in pcDNA3 (10). A derivative of
this clone was constructed such that N-terminal methionine of EBP2 was re-
placed by an in-frame FLAG epitope (AGP104). Independently, wild-type EBP2
was amplified from pcDNA3-EBP2 with oligonucleotides AGO37 and AGO38
(show below): AGO37, ATTGGCCAGTCAGGCCCAACCATGGACACTCC
CCCGCTCTCGGATTC; and AGO38, CCCGGGGGAAGCTTGGTGTGTTC
TGTTCTTCATCTTCTC.
The PCR product was cut with SfiI and HindIII and inserted into AGP102 (48)
to construct an EBP2-DBD fusion protein (AGP107). The coding sequence for
this fusion protein was also moved into AGP164 to create a retroviral expression
vector for EBP2-DBD (AGP178). Sequences for all of the plasmids used in the
present study can be found online (http://ebv.mimnet.northwestern.edu/plas-
mids).
Nitrocellulose filter-binding assays to measure AT hook activity. To produce
baculo-EBNA1 (bEBNA1), a cDNA clone of the 1553 version of EBNA1 (2) was
cloned into the baculovirus transfer vector pBACgus3 (Novagen). Recombinant
baculovirus was generated by standard methodology and used to infect Sf9 cells.
Cell supernatants were concentrated and loaded onto a Talon immobilized metal
affinity chromatography column (Clontech). Eluted protein was then cleaved
with enterokinase to remove the S-tag and His6 tag added by the vector. The
baculovirus-expressed protein (bEBNA1) was ca. 90% pure by colloidal Coo-
massie staining. Domains A and B were purified as His6-tagged fusion proteins
as described previously (39), after which the His6 tag was proteolytically re-
moved. These proteins were determined to be at least 95% pure by colloidal
Coomassie blue staining and used in filter-binding assays as described recently to
examine the DNA-binding specificity of the Schizosaccharomyces pombe and the
human origin recognition complex (ORC) (32, 55). To avoid the possibility that
the binding observed was due to contaminating bacterial proteins, assays were
also performed with chemically synthesized peptides corresponding to the pre-
sumptive AT hook regions of EBNA1. The domain B peptide is contained
entirely within domain B, whereas the domain A peptide has 3 aa that are amino
terminal to the start of domain A. Identical results were obtained with the
peptides and bacterially expressed proteins. The sequences of the peptides, with
the presumptive AT hook underlined, were follows: domain A hook region
peptide, Ac-GPQRRGGDNHGRGRGRGRGRGGGRPG-NH2 (EBNA1 aa 30
to 55); and domain B hook region peptide, Ac-GGGRGRGGSGGRGRGGSG
GRGRGGS-NH2 (EBNA1 aa 326 to 350).
Peptides were acetylated at the amino terminus and amidated at the carboxy
terminus. Purified HMGA1a [HMG-I(Y)] was kindly provided by Raymond
Reeves (Washington State University), and a peptide corresponding to the first
two AT hooks of HMGA1a was a gift from Jonathan Leis (Northwestern Uni-
versity).
Filter-binding assays were conducted in a final volume of 15 l, containing 25
mM HEPES-NaOH (pH 7.5), 50 mM NaCl, 5 mM magnesium acetate, 1 mM
dithiothreitol, 0.1 mg of bovine serum albumin/ml, 125 ng of 32P-labeled DNA
probe, 1 g of poly(dA-dC)(dG-dT) as competitor. After incubation for 15 min
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at 25°C, the reaction volume was increased to 1 ml by the addition of wash buffer
(25 mM HEPES-NaOH [pH 7.5], 50 mM NaCl, 5 mM magnesium acetate, 1 mM
dithiothreitol) and then filtered through nitrocellulose filters (0.45 m, type
HA). Filters were then washed three times with 1 ml of wash buffer and dried,
and the radioactivity absorbed on the filter was counted by liquid scintillation
counting. The probe used for binding was poly(dA-dT), whereas poly(dG-dC), a
HindIII digest of lambda, and purified oriP DNA were used as competitors.
Probe and competitors were purchased from Sigma, except oriP DNA, which was
excised from AGP74 as a BamHI-KpnI fragment. According to the manufactur-
er’s specifications, the poly(dA-dT) ranged in length from 3,000 to 5,000 bp, and
the poly(dG-dC) ranged in length from 800 to 2,500 bp. Binding reactions
typically contained 15 ng (2.6 pmol) of domain A, 15 ng (3 pmol) of domain B,
2.5 pmol of the respective peptides, 15 ng (1.3 pmol) of HMGA1a, 2.5 pmol of
the HMGA1a peptide, or 50 ng (1.3 pmol) of baculovirus expressed EBNA1 that
lacks the glycine-alanine repeats.
Cell culture and generation of stable 293 cell lines. The human EBNA1
expressing cell line 293/EBNA1 is a derivative of 293 cells (18) that stably express
wild-type EBNA1. 293/1A-DBD cells are a derivative of 293 cells, which stably
express through retroviral integration domain A fused to the DBD of EBNA1
(AGP171). 293/2A-DBD cells are a derivative of 293 cells, which stably express
through retroviral integration two A domains fused to the DBD of EBNA1
(AGP172). 293/3A-DBD cells are a derivative of 293 cells, which stably express
through retroviral integration three A domains fused to the DBD of EBNA1
(AGP173). 293/EBP2-DBD cells are a derivative of 293 cells, which stably ex-
press through retroviral integration human EBP2 fused to the DBD of EBNA1
(AGP178). All cells were propagated in Dulbecco modified Eagle medium sup-
plemented with 10% fetal bovine serum and antibiotics. G418 was supplemented
for 293/EBNA1 cells at a final concentration of 200 g/ml and supplemented at
300 g/ml for the other 293 derivatives. All cells were grown in 37°C in a
humidified 5% CO2 atmosphere.
A derivative of 293 cells that stably express the MLV Gag and Pol proteins
(gp293) was used to package and propagate retroviral vectors. GP293 cells were
grown in the conditions described above to a density of 50%, at which time
the cells were cotransfected by the calcium phosphate method with 10 g of
AGP171, AGP172, or AGP173 and 1 g of vesicular stomatitis virus protein G
expression plasmid (AGP154) to pantropically pseudotype the packaged virus.
One hundred nanograms of a simian virus 40 large T-antigen expression plasmid
(AGP5) was included in the cotransfection, because large T antigen dramatically
increases the titers of retroviral vectors expressed from AGP164 and its deriva-
tives. After 16 h, the medium was replaced. After 72 h, the virus-containing
medium was collected and centrifuged to pellet the suspended cells, and then
5 ml of virus-containing medium was used to infect 293 cells grown to 50% cell
density in a 10-cm dish. To increase the efficiency of retroviral infection, Poly-
brene was added during the infection at a final concentration of 7.5 g/ml. After
48 h, infected cells were split 1:30 and then placed under selection with 300 g
of G418/ml. Clones were obtained within 2 to 3 weeks of selection. Expression of
the appropriate protein in each cell line was confirmed by immunoblot and
indirect immunofluorescence (see Results).
Calcium phosphate transfection. Cells were transfected by the calcium phos-
phate method as described previously (36). For colony formation assays and
Southern blots, transfections were normalized by the inclusion of 1 g of a
cytomegalovirus-EGFP expression plasmid, 2145, in each transfection. Upon
harvest, a fraction of the cells were profiled by using a Becton Dickinson FAC-
Scan or FACSCalibur. Transfection efficiency was measured as the fraction of
GFP-expressing live cells quantified by using CellQuest software (Becton Dick-
inson, Franklin Lakes, N.J.).
Coimmunoprecipitation of EBNA1 mutants with human EBP2. Coimmuno-
precipitation was performed by the following protocol. 293 cells were cotrans-
fected with expression plasmids for FLAG-EBP2, along with expression plasmids
for WT-EBNA1, 1A-DBD, 2A-DBD, 3A-DBD, or a derivative of WT-EBNA1
that lacks aa 386 to 450, because this region of EBNA1 is also missing from
1A-DBD, 2A-DBD, and 3A-DBD. At 2 days posttransfection, cells were har-
vested, washed with phosphate-buffered saline (PBS), lysed with 2 ml of immu-
noprecipitation buffer (20 mM Tris [pH 7.5], 250 mM NaCl, 0.5% NP-40, 0.5 mM
EDTA, 0.1 mM AEBSF, and 0.5% protease inhibitor cocktail [Sigma]), and
incubated on ice for 10 min. Extracts were pelleted at 50,000  g for 20 min at
4°C. Under these conditions, EBNA1 is largely extracted away from the pelleted
chromatin. Supernatants were used for coimmunoprecipitation. Then, 10 g of
K67.3 anti-EBNA1 DBD was added per 1 ml of cell extract and incubated with
end-over-end mixing for 2 h at 4°C. Next, 50 l of prewashed protein A/G-
Sepharose (Santa Cruz Biochemicals) was then added to the extract and mixed
end over end for 1 h at 4°C. Immunoprecipitates were washed three times with
lysis buffer, mixed with 2 sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) sample buffer, and boiled for 5 min. Samples were then
subjected to immunoblotting as described below, with membrane blocking per-
formed in Blotto buffer (50 mM Tris [pH 7.5], 100 mM NaCl, 0.1% Tween 20,
and 10% dry milk). Samples were probed by using either a monoclonal anti-
EBNA1 antibody (1H4) or a monoclonal anti-FLAG antibody (M2; Sigma) as
the primary antibody.
Immunoblotting. Immunoblotting was done according to standard protocols
(36). Briefly, extracts from 1.5  106 cells were separated on an SDS–10%
polyacrylamide gel and transferred to a polyvinylidene difluoride membrane.
After a blocking step for 1 h with 10% nonfat milk and 0.05% Tween 20, the
membrane was treated with a rabbit polyclonal anti-EBNA1 serum diluted
1:1,000 (34) in blocking solution for 1 h at 37°C. The secondary antibody was a
horseradish peroxidase-conjugated goat anti-rabbit antibody diluted 1:10,000 in
blocking solution for 1 h at 37°C. Membranes were briefly washed once with
0.5% Tween 20 in PBS and once briefly with deionized water. Detection was
performed by conventional chemiluminescence methods.
Metaphase chromosome spread preparation. Isolation of metaphase chromo-
somes was done as described previously (51). Spreads were prepared from 293
cells and 293 cells expressing wild-type EBNA1 or mutant derivatives that were
blocked in early metaphase with Colcemid (0.1 g/ml). Cells were dropped onto
poly-L-lysine-coated glass coverslips (Fisher, Hanover Park, Ill.) and dehydrated
with increased ethanol washes. After PBS rehydration, slides were visualized by
indirect immunofluorescence.
Indirect immunofluorescence and deconvolution microscopy. Indirect immu-
nofluorescence and image capture was performed similarly to that done previ-
ously (48), except that DNA was counterstained with Hoechst 33342 instead of
DAPI (4,6-diamidino-2-phenylindole). For detection of EBP2-DBD in intact
cells stalled in metaphase, 293/EBP2-DBD cells were treated with Colcemid,
harvested, and seeded onto coverslips before the indirect immunofluorescence
procedure. All EBNA1 derivatives were recognized by the primary rabbit poly-
clonal K67.3 antibody, which recognizes the EBNA1 DBD. Human EBP2 was
detected by a primary mouse monoclonal antibody (a kind gift of Ben Valdez and
Harris Busch). FLAG-EBP2 was expressed 2 days posttransfection of 10 g of
AGP104 and detected by a primary anti-FLAG mouse monoclonal antibody
(Chemicon) at 1:2,000. The secondary antibodies used are specified with each
figure. For cell imaging, an Olympus IX inverted fluorescence microscope and a
Photometrix cooled charge-coupled device camera (CH350/LCCD) utilizing
DeltaVision software from Applied Precision, Inc. (Seattle, Wash.) was used for
data collection. Forty 100-nm optical sections (Z-sections) were obtained
through the depth of the cell, and DeltaVision software (softWoRx) was used to
deconvolve these images into individual layers. DeltaVision softWoRx uses a
constrained iterative deconvolution algorithm to remove out-of-focus blur in
fluorescence optical sections and was set for a minimum of 15 iterative cycles.
Fluorescence emission was linear over a 100-fold range of emission signals within
which fluorescein isothiocyanate (FITC), rhodamine, and DAPI/Hoechst 65535
signals were detected. Images were acquired with 100 NA 1.35 objective lenses
either with or without 1.5 optical enhancement.
Colony formation assays to assess plasmid maintenance and partitioning. The
ability of 293 derivatives stably expressing the domain A derivatives of EBNA1
to stably partition an oriP plasmid was performed as described previously (21,
48), with transfection of AGP74 replication reporter.
Southern hybridization analysis to assess plasmid replication. The detection
of replicated, oriP plasmids in the 293 derivative cell lines was performed as
previously described unless otherwise noted (21, 23, 48). To assess the dominant-
negative effect of EBP2-DBD on plasmid replication by EBNA1, 10 g of an
EBP2-DBD expression plasmid containing wild-type oriP (AGP113) was trans-
fected into 293/EBNA1 cells.
RESULTS
The A and B domains of EBNA1 specifically and directly
bind AT-rich DNA in vitro. A schematic representation of
EBNA1 is shown in Fig. 1A, along with sequences within
domain A and domain B that are similar to AT hook motifs
present within the cellular AT hook proteins HMGA1a and
MeCP2/MBD2a, both of which are known to bind the AT-rich
scaffold-associated regions (SARs) of mammalian chromo-
somes (4, 13, 52, 56). HMGA1a is known to associate with
AT-rich DNA through its AT hooks (5). We therefore tested
whether domains A and B of EBNA1 would function as AT
VOL. 78, 2004 EBNA1 BINDS CHROMOSOMES BY USING AMINO-TERMINAL AT HOOKS 11489
hooks in vitro by using nitrocellulose filter-binding assays that
have recently been used to characterize the DNA-binding
specificity of the S. pombe or human ORC (12, 32, 55). Do-
mains A and B were expressed and purified from bacteria or
were chemically synthesized as peptides and then tested for
their ability to bind AT-rich DNA by using labeled poly(dA-
dT) as probe. As a control, binding assays were performed with
purified HMGA1a or a peptide corresponding to the first two
AT hooks of HMGA1a. The results of this experiment are
shown in Fig. 1B. HMGA1a bound 50% of the labeled
poly(dA-dT) probe (62.5 ng) at a protein concentration of 0.11
M. Similar results were obtained by using a peptide corre-
sponding to the first two AT hooks of HMGA1a (50% binding
at a 0.5 M concentration of peptide). Under these conditions,
purified domain A and domain B also bound the poly(dA-dT)
probe, such that a 0.23 M concentration of domain A bound
50% of the probe and 0.13 M concentration of domain B
bound 50% of the probe. Moreover, 0.8 to 1.0 M concentra-
tions of peptides corresponding to the presumptive AT hooks
of domains A and B bound 50% of the poly(dA-dT) probe.
We next examined whether this association was specific for
AT-rich DNA, by adding various cold competitor DNAs dur-
ing the binding reaction (Fig. 1C). A 1,000-fold excess of cold
poly(dG-dC) or a HindIII digest of phage lambda DNA did
not compete for the association of HMGA1a (0.1 M protein),
domain A (0.2 M protein), or domain B (0.2 M protein)
with the labeled poly(dA-dT) probe. In contrast, cold poly(dA-
dT) effectively competed for the association of HMGA1a, do-
main A, and domain B with the labeled probe. Similar results
were observed in experiments with peptides corresponding to
the AT hook regions of HMGA1a and the presumptive AT
hooks within domains A and B (0.2 M peptide). When as-
says were performed with labeled poly(dG-dC) as probe, cold
poly(dA-dT) remained an effective competitor for all three
proteins tested (data not shown), indicating that domains A
and B share an affinity for AT-rich DNA with HMGA1a.
Experiments were also performed with baculovirus-expressed
EBNA1, bEBNA1 (lacking the Gly-Ala repeats), to test wheth-
er domains A and B have AT hook activity in the context of the
entire protein (Fig. 1C). bEBNA1 bound 50% of the probe at
a 0.1 M protein concentration (data not shown), and this
binding was specifically competed for by poly(dA-dT) but not
by lambda DNA or poly(dG-dC). Because this protein also has
EBNA1’s DBD, we included oriP DNA as a competitor and
found that it failed to effectively compete the binding of
EBNA1 for AT-rich DNA. This result confirmed that the ami-
no terminus of EBNA1 has an affinity for AT-rich DNA.
Drugs such as distamycin A and netropsin are synthetic AT
hook analogs that bind AT-rich DNA sequences in the minor
groove and displace AT hook proteins from binding in the
minor groove (8, 44). This property of distamycin A has been
used previously to demonstrate that HMGA1a associates with
AT-rich DNA in the minor groove (44). We tested whether
preincubation of the poly(dA-dT) probe with distamycin A
would block binding by domains A and B and included
HMGA1a as a control. Interestingly, distamycin A at 5 to 10
M, the concentration at which HMGA1a was blocked from
DNA binding, inhibited both the A domain and the B domain
from binding the poly(dA-dT) probe (Fig. 1D). Similar results
were obtained with the HMGA1a peptide and with the pep-
tides corresponding to the AT hook motifs within domains A
and B and with bEBNA1. Netropsin also blocked the associa-
tion of domain A, domain B, and HMGA1a with poly(dA-dT)
(data not shown).
In summary, these data indicate that domains A and B can
bind AT-rich DNA directly in a manner very similar to
FIG. 1. (A) Schematic diagram of EBNA1. Domain A spans aa 33 to 89, and domain B spans aa 328 to 378. The presumptive AT hooks within
domains A and B are compared to the known AT hooks of HMGA1a (GenBank accession number NM145899) and MBD2a (GenBank accession
number NP003918). Amino acid mismatches are italicized and underlined. (B) Bacterially expressed domains A and B bind AT-rich DNA in vitro.
One hundred twenty-five nanograms of labeled poly(dA-dT) probe was incubated in the presence of 1 g of poly(dA-dC)(dG-dT), and increasing
amounts of bacterially expressed HMGA1a, domain A or domain B, after which reactions were stopped and filtered through nitrocellulose. Ni-
trocellulose filters were washed and scintillation counted. The binding curve obtained with each protein is indicated by the legend within the graph.
(C) The association between AT-rich DNA and domains A and B is specific. We incubated 0.1 M HMGA1a, 0.2 M domain A, 0.2 M domain
B, or 0.1 M bEBNA1 with 125 ng of labeled poly(dA-dT) probe, 1 g of poly(dA-dC)(dG-dT), and increasing amounts of cold poly(dA-dT),
poly(dG-dC), or a HindIII digest of phage lambda as competitor DNA prior to assay by filter binding. For bEBNA1, a fragment of AGP74 that
contains oriP was also used as a cold competitor. The binding curve obtained with each competitor is indicated by the legend within each graph.
For all of the proteins tested, only cold poly(dA-dT) functioned as an effective competitor. (D) Distamycin A inhibits the association of HMGA1a,
domain A, and domain B with poly(dA-dT). Increasing amounts of distamycin A were preincubated with the labeled poly(dA-dT) probe (125 ng)
for 10 min. At this time, 0.2 M HMGA1a, domain A, or domain B was added, along with 1 g of poly(dA-dC)(dG-dT). Reactions were incubated
for a further 20 min and then assayed by filter binding, followed by scintillation counting.
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HMGA1a and that this association is very likely through AT
hooks within domains A and B associating with the minor
groove of AT-rich DNA. As such, domains A and B cannot be
distinguished biochemically from the prototypic AT hook pro-
tein, HMGA1a.
Construction and expression of EBNA1 derivatives that lack
domain B but contain one or more copies of domain A. Be-
cause EBP2 associates exclusively with domain B (50), we
constructed three derivatives of EBNA1 that lacked domain B
and contained one (1A-DBD), two (2A-DBD), or three (3A-
DBD) copies of domain A directly fused to the DBD of
EBNA1. It should be noted that these derivatives all contain
the nuclear localization signal (NLS) of EBNA1 (aa 379 to
386) but lack aa 386 to 450, a region that we have previously
shown is not necessary for EBNA1’s functions in the stable
replication and partitioning of oriP plasmids (48). 1A-DBD,
2A-DBD, and 3A-DBD are schematically represented in Fig.
2A. The individual A domains in proteins that contained mul-
tiple copies of domain A were separated by a short peptide
linker. Derivatives of 293 cells were created by retroviral trans-
duction that stably expressed each derivative of EBNA1, and
expression was confirmed through immunoblot analysis (Fig.
2B). All of the derivatives migrated at the expected sizes.
Domain B is required for EBNA1 to associate with EBP2 but
not for EBNA1 to associate with metaphase chromosomes.
Next, we sought to confirm that 1A-DBD, 2A-DBD, and 3A-
DBD no longer associated with EBP2, since they lacked do-
main B (50). We examined this by coimmunoprecipitation,
such that FLAG-EBP2 was transiently overexpressed in 293
cells, along with wild-type EBNA1, 1A-DBD, 2A-DBD, 3A-
FIG. 2. (A) Schematic representation of EBNA1 and derivatives lacking domain B but containing one or more copies of domain A. The three
A domain derivatives contained one, two, or three copies of domain A (aa 33 to 89) fused to the EBNA1 NLS (aa 379 to 386), and the DBD (aa
451 to 641). In derivatives that contain two or more A domains, adjacent A domains are separated by a short peptide linker with the sequence
QSWS. The version of EBNA1 used here contains only five copies of the Gly-Gly-Ala repeat between domains A and B but functions like wild-type
EBNA1 (2, 48). Retroviral vectors expressing EBNA1, DBD, 1A-DBD, 2A-DBD, and 3A-DBD were used to transduce 293 cells and establish cell
lines that stably express each of these proteins. (B) An immunoblot analysis of clones of 293 cells that express the proteins described above. Cell
extracts were prepared from 293 cell clones and immunoblotted with a rabbit polyclonal antibody that recognizes the DBD of EBNA1. The cell
line used is indicated above each lane. All of the derivatives migrated at their expected mobilities relative to wild-type EBNA1.
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DBD, or a derivative of wild-type EBNA1 that lacks aa 386
to 450 (EBNA1386-450) (Fig. 3). Whole-cell extracts were
immunoprecipitated with a rabbit polyclonal antibody to
EBNA1’s DBD. Immunoprecipitates were immunoblotted
with a rat monoclonal antibody to EBNA1 (Fig. 3A) or a
mouse monoclonal anti-FLAG antibody to detect EBP2 (Fig.
3B). As can be seen in Fig. 3B, EBP2 was readily coimmuno-
precipitated by derivatives of EBNA1 that contained domain B
but not by 1A-DBD, 2A-DBD, or 3A-DBD. A total of 5% of
the extracts used for immunoprecipitation were directly exam-
ined for the expression of FLAG-EBP2. This analysis, shown in
Fig. 3C, confirmed that FLAG-EBP2 was expressed approxi-
mately equivalently in all of the transfections. An immunoblot
performed against EBNA1 confirmed that all of the derivatives
of EBNA1 were immunoprecipitated with the polyclonal anti-
body. In our experience, deletion of aa 386 to 450 increases the
expression of EBNA1 in transient transfection, which is why
EBNA1386-450, 1A-DBD, 2A-DBD, and 3A-DBD are ex-
pressed at higher levels than EBNA1 (Fig. 3A).
These results confirm those reported previously (50) that
domain B is absolutely required for an association of EBNA1
with EBP2. We next examined whether this association was
essential for EBNA1 to bind metaphase chromosomes. 293,
293/DBD, 293/EBNA1, 293/1A-DBD, 293/2A-DBD, and 293/
3A-DBD cells were stalled in early metaphase through
Colcemid treatment (0.1 g/ml) for 16 h and used to isolate
metaphase spreads that were subjected to indirect immunoflu-
orescence to detect whether 1A-DBD, 2A-DBD, and 3A-DBD
associated with metaphase chromosomes. This analysis is
shown in Fig. 4. Chromosomes isolated from 293/EBNA1 cells
showed discrete, punctate staining on metaphase chromo-
somes similar to what we have described previously for
EBNA1 and HMGA1a-DBD (48). No chromosome-associated
staining was observed in chromosomes isolated from 293/DBD
cells or from the negative-control 293 cells. All three deriva-
tives that lacked domain B showed a staining pattern on meta-
phase chromosomes very similar to wild-type EBNA1, al-
though the expression levels of these proteins differed.
From this analysis, we conclude that although domain B is
absolutely required for an association of EBNA1 with EBP2, it
is not essential for EBNA1 to associate with metaphase chro-
mosomes. As a corollary, binding EBP2 cannot be the only
mechanism by which EBNA1 associates with metaphase chro-
mosomes. However, is this binding, in the absence of EBP2,
FIG. 3. Domain B is required for EBNA1 to associate with the cellular protein EBP2. 293 cells were transiently transfected with a FLAG-EBP2
expression plasmid and expression plasmids for the indicated derivative of EBNA1 (indicated above each lane) or with just the FLAG-EBP2
expression plasmid (lane No EBNA1). Extracts were prepared as described in the text and immunoprecipitated with a rabbit polyclonal antibody
to the DBD of EBNA1. Immunoprecipitates were analyzed by SDS-PAGE and then immunoblotted with a rat monoclonal antibody to EBNA1
(A) or a mouse monoclonal antibody to FLAG-EBP2 (B). Only EBNA1 and EBNA1386-450, which both contain domain B, were observed to
immunoprecipitate FLAG-EBP2. (C) An immunoblot against FLAG-EBP2 with a 5% load of whole-cell extract from each of 293 cell cotrans-
fections, indicating that the expression of FLAG-EBP2 was approximately equal in all transfections. The antibodies used for immunoprecipitation
(IP) or immunoblotting (IB) are indicated adjacent to each blot. The positions of molecular mass markers on the SDS-PAGE gels are also
indicated in kilodaltons.
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sufficient to support the stable replication and partitioning of
oriP plasmids?
1A-DBD, 2A-DBD, and 3A-DBD support the replication and
partitioning of oriP plasmids. Our previous results led us to
hypothesize that metaphase chromosome tethering is a re-
quirement for the replication of oriP plasmids by EBNA1 in
mammalian cells (48). Because 1A-DBD, 2A-DBD, and 3A-
DBD bound to metaphase chromosomes without binding
EBP2, we tested whether they were still competent to replicate
an oriP plasmid. For this, the oriP replication reporter plasmid,
AGP74, was transfected into 293/EBNA1, 293/1A-DBD, 293/
2A-DBD, and 293/3A-DBD cells. Hirt DNAs were isolated 1
and 3 weeks posttransfection, digested with DpnI, linearized
with XbaI, and quantified by Southern blotting (Fig. 5 and
Table 1). By 7 days posttransfection, replicated oriP reporter
was readily detected in all cell types, which reinforces our
previous conclusion that metaphase chromosome association is
required for the replication of oriP plasmids (48). However, at
3 weeks posttransfection, the levels of replicated oriP reporter
plasmid detected from 2A-DBD and 3A-DBD were similar to
that observed with wild-type EBNA1 (Fig. 5 and Table 1). In
contrast, little to no replicated oriP reporter plasmid was ob-
served with 1A-DBD at 3 weeks posttransfection, a finding
consistent with previous results obtained in C33A cells (50).
Our results with 2A-DBD and 3A-DBD suggested that the
ability of EBNA1 to stably replicate an oriP plasmid was de-
pendent upon the affinity of EBNA1 for metaphase chromo-
somes. Wild-type EBNA1 associates via two regions—A and
B—as does 2A-DBD. We speculated that we might be able to
rescue the stable replication defect in 1A-DBD by increasing
the number of EBNA1 binding sites on the replication reporter
plasmid. Simplistically, we felt this would increase the amount
of 1A-DBD on the plasmid and therefore increase the proba-
bility that the replication reporter would associate with meta-
phase chromosomes. Thus, we constructed a derivative of
AGP74 which has an FR containing 30 EBNA1 binding sites
FIG. 4. 1A-DBD, 2A-DBD, and 3A-DBD bind metaphase chromosomes. Metaphase chromosomes were isolated from 293, 293/DBD,
293/EBNA1, 293/1A-DBD, 293/2A-DBD, and 293/3A-DBD cells stalled in mitosis by Colcemid treatment. Indirect immunofluorescence was
performed by using the K67.3 rabbit polyclonal antibody against the DBD of EBNA1. Images of individual layers (40 z-sections of 100 nm each)
were captured using a 100 objective, with 1.5 optical enhancement, and deconvolved by using softWoRx. The cell line used for metaphase
chromosome isolation is indicated above each panel. All three proteins were observed to localize to metaphase chromosomes in discrete punctate
spots that resemble those observed previously with wild-type EBNA1 or HMGA1a-DBD (48).
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FIG. 5. EBNA1 derivatives 1A-DBD, 2A-DBD, and 3A-DBD support the episomal replication of oriP plasmids. (A) The oriP replication
reporter plasmid, AGP74 (20FR), was transfected into 293/EBNA1, 293/1A-DBD, 293/2A-DBD, or 293/3A-DBD cells, along with a GFP
expression plasmid. Two days after transfection, live transfected cells were recovered and subjected to puromycin selection for an additional 5 days
(total  7 days) or 19 days (total  21 days). At this time, episomal DNAs were recovered, digested with DpnI, linearized, and quantified by
Southern blotting. The cell line transfected is indicated above each lane, as is the time point at which episomal plasmids were recovered. The
migration of standards is indicated by an arrowhead and “A,” and the linearized plasmid DNA is indicated by an arrowhead and “B.” Copy
numbers of replicated plasmids per cell at each time point from three replicates of this experiment are indicated in Table 1. 1A-DBD only
supported the replication of AGP74 (20FR) up to 7 days posttransfection but not at the later time point. 2A-DBD and 3A-DBD supported
replication of this plasmid at both time points. (B) The replication defect in 1A-DBD is compensated by a plasmid, AGP264, that contains 30
EBNA1-binding sites in FR. AGP74 (20FR) or AGP264 (30FR) were transfected into 293/1A-DBD cells, which were processed as in panel A.
Replicated episomal DNAs were detected for both plasmids at 7 days posttransfection, but only for AGP264 (30FR) at 21 days posttransfection,
indicating that increasing the number of EBNA1 binding sites in FR compensated for the defect in 1A-DBD. Copy numbers for replicated plasmids
per cell at each time point from two replicates of this experiment are indicated in Table 1. As a control for DpnI digestion, AGP74 was transfected
into 293 (C) or 293/EBNA1 cells (D). Hirt DNAs were recovered at 4, 5, or 6 days posttransfection, digested with DpnI, linearized, and quantified
by Southern blot. The DpnI fragments are indicated by “C,” whereas DpnI-resistant DNAs and markers are indicated as previously.
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(AGP264) and tested the ability of 1A-DBD to support the
stable replication of this novel replication reporter plasmid. As
shown in Fig. 5B and Table 1, when there are 30 EBNA1
binding sites in FR, 1A-DBD supports the stable replication of
an oriP plasmid, supporting our simple model.
Domains A and B both have AT hook activity in vitro like
HMGA1a, but only domain B associates with EBP2. Our re-
sults examining the stable replication of oriP plasmids indicate
that this activity of EBNA1 correlates well with its AT hook
activity. However, are the plasmids that are stably replicated by
1A-DBD, 2A-DBD, and 3A-DBD partitioned or does parti-
tioning require an association with EBP2?
We therefore tested whether oriP plasmids were partitioned
efficiently by the 1A-DBD, 2A-DBD, and 3A-DBD proteins in
comparison to wild-type EBNA1 by using colony formation
assays. Such assays test the ability of replicated plasmids to be
distributed as a single cell proceeds to form a colony of cells. If
partitioning is dependent upon an association with EBP2, all
three proteins should not perform well in this assay. On the
other hand, our previous results with HMGA1a-DBD (which
has three AT hooks) suggested that partitioning correlated
with AT hook activity. If this were also true for EBNA1, then
we would expect that 1A-DBD would partition plasmid inef-
ficiently (with only one AT hook region), whereas 2A-DBD
and 3A-DBD should partition plasmids with an efficiency that
is close to that of wild-type EBNA1. Colony formation assays
were performed by using AGP74 as described in Materials and
Methods, and the number of transfected, surviving, cells that
proceeded to form colonies that were 2 mm in size were
scored 21 days posttransfection. These data are presented in
Table 2. 1A-DBD is very ineffective at partitioning but sub-
stantially above background for the assay. In contrast, 2A-
DBD and 3A-DBD are approximately as efficient as wild-type
EBNA1.
Contributions of EBP2 to the replication of oriP plasmids in
human cells. We and others have shown that the entire amino
terminus of EBNA1 can be functionally replaced by cellular
proteins that associate with metaphase chromosomes (24, 48).
This strategy has also been employed successfully to study the
association of LANA protein of KSHV with chromosomes
(49). Because EBP2 is proposed to mediate EBNA1’s associ-
ation with metaphase chromosomes, we tested whether the
amino terminus of EBNA1 could be functionally replaced by
EBP2. This new fusion, EBP2-DBD, is schematically depicted
in Fig. 6A. It contains full-length wild-type EBP2 (without any
tags), fused to aa 379 to 386 of EBNA1 (the NLS) and then aa
451 to 640 (the DBD). We constructed a derivative of 293 cells
that expressed this fusion, 293/EBP2-DBD, via retroviral trans-
duction and confirmed expression by immunoblot (data not
shown).
To characterize the EBP2-DBD protein, we compared its
intracellular localization relative to native EBP2. p40/EBP2
was first reported by Busch and coworkers to be a strictly
nucleolar protein (10) in HeLa cells, although other analyses in
HeLa and other cells suggest that it is both nucleolar and
associated with chromatin (26, 58). We therefore performed
experiments in both HeLa and 293 cells, the results of which
are shown in Fig. 6B. HeLa cells were transfected with GFP-
tagged MPP10 (a nucleolar marker) (57). Interphase cells were
then processed for indirect immunofluorescence by using de-
convolution (or confocal) microscopy with a monoclonal anti-
body to native EBP2. As shown in Fig. 6B, GFP-MPP10
stained several nucleoli per cell, specifically coinciding with
where DAPI staining was weakest inside nuclei (see Fig. 6B,
the first two panels). Consistent with the previous character-
ization of EBP2 (10), endogenous EBP2 was found to be
strictly nuclear and heavily enriched within nucleoli (see Fig.
6B, the third and fourth panels). The final merged image in
Fig. 6B shows a close colocalization of native EBP2 and GFP-
MPP10 within the nucleoli of HeLa cells. Identical results were
obtained for EBP2 localization in 293 cells (data not shown).
We could not examine the localization of EBP2-DBD by using
the monoclonal antibody to EBP2, since it would detect both
native and fused proteins. We therefore transfected 293/EBP2-
DBD cells with FLAG-EBP2. The localization of FLAG-EBP2
was examined by using a monoclonal antibody to the FLAG
epitope, and localization of EBP2-DBD was examined by using
polyclonal antibodies to the DBD (Fig. 6C). As shown in the
second panel, EBP2-DBD, like endogenous EBP2, was specif-
ically enriched within DAPI-negative nucleoli, as was FLAG-
EBP2. There was almost complete overlap between the local-
ization of EBP2-DBD with FLAG-EBP2 (Fig. 6C, last panel).
Our results indicate that in interphase HeLa and 293 cells,
EBP2, FLAG-EBP2, and EBP2-DBD are all localized to nu-
cleoli, with very little to no chromatin staining, a finding con-
TABLE 1. Average copy number of DpnI-resistant replication
reporter plasmids 7 and 21 days posttransfection in 293 cells
expressing 1A-DBD, 2A-DBD, 3A-DBD, or EBNA1
Cell line
transfected
Replication reporter plasmida
(mean no. of plasmids  SD)
AGP74 (20 FR) at: AGP264 (30 FR)b at:
7 days 21 days 7 days 21 days
293/1A-DBD 11  3 1.1  0.7 34  11 40  8
293/2A-DBD 35  16 43  17 ND ND
293/3A-DBD 42  8 37  12 ND ND
293/EBNA1 18  7 27  15 ND ND
a Numbers of episomal DpnI-resistant plasmids detected at the indicated time
point after transfection in the presence of puromycin selection. The numbers
represent the means and standard deviations of three experiments, except as
noted.
b Numbers represent the means and standard deviations of two experiments.
ND, not done.
TABLE 2. Colony formation efficiency of AGP74 (pPUR-oriP) in
293 cells that stably express the 1A-DBD, 2A-DBD, and 3A-DBD
derivatives of EBNA1
Cell line No. of puromycin-resistant coloniesa
293 ..................................................................................... 1  1
293/EBNA1.......................................................................1,222.4  75.5
293/1A-DBD..................................................................... 118.6  28.9
293/2A-DBD..................................................................... 750.5  68.2
293/3A-DBD..................................................................... 951  117.4
a Data represent the number of puromycin-resistant colonies formed per 2 
105 live, GFP- positive cells plated 48 h posttransfection. Selection was initiated
4 days posttransfection and continued for 17 days. Each cell line was transfected
at least twice. At least two plates were counted from each transfection. Only
colonies that were 2 mm were counted.
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sistent with observations published previously for EBP2/p40, in
which no chromatin staining was observed (10).
We tested whether EBP2-DBD could support the replica-
tion of oriP plasmids by transfecting 293/EBP2-DBD cells with
the oriP replication reporter plasmid, 1033 (28). DNA’s were
extracted, digested with DpnI to remove unreplicated DNA,
and examined by Southern blot for episomal plasmids 4 and 21
days posttransfection in the absence of drug selection (Fig. 7
and Table 3). Plasmid 1033 replicated robustly in 293/EBNA1
cells. In contrast, replicated plasmid 1033 DNA was present at
substantially reduced levels by 4 days posttransfection and
could not be detected by 21 days posttransfection in 293/EBP2-
DBD cells. We have previously shown that another fusion
protein that also does not support transient replication of oriP
plasmids, HMG1-DBD, functions as a dominant-negative in-
hibitor of wild-type EBNA1. We tested whether EBP2-DBD
would function as such an inhibitor by examining the replica-
tion of an EBP2-DBD expression plasmid that also contains
oriP (AGP113) in 293/EBNA1 cells. No replicated DNA was
detected at 4 days posttransfection or beyond, confirming that
EBP2-DBD can bind oriP but does not functionally support the
replication or partitioning of oriP plasmids (data not shown).
Our previous results indicated that even transient replica-
tion of oriP plasmids correlated with an association between
EBNA1 and metaphase chromosomes (48). We therefore
tested whether EBP2-DBD, as well as native EBP2, associated
with metaphase chromosomes. This analysis was performed by
using deconvolution microscopy with a 100 objective lens,
with or without1.5 optical enhancement, and 40 z-sections of
100 nm (Fig. 8). 293/EBP2-DBD cells were blocked with Col-
FIG. 6. (A) Schematic representation of the EBP2-DBD fusion protein in which the EBNA1 amino terminus (aa 1 to 450) is replaced by human
EBP2. EBNA1’s NLS (aa 379 to 386) was added to the fusion junction. A retrovirus vector expressing EBP2-DBD was used to transduce 293 cells
and create a 293 derivative cell line that stably expresses this protein (293/EBP2-DBD). (B) Endogenous EBP2 localizes to nucleoli in interphase
human cells. The stain or antibody used is indicated above each panel. HeLa cells were transfected with an expression plasmid for the nucleolar
protein MPP10 fused to GFP to locate nucleoli (57). MPP10-GFP largely localizes to DAPI-negative regions (compare panel DAPI to panel
DAPIMPP10). EBP2 largely colocalizes with MPP10 (compare panel DAPIMPP10 to panels DAPIEBP2 and MERGE). This colocalization
indicates that the majority of EBP2 is localized to nucleoli as observed previously (10). (C) EBP2-DBD colocalizes with EBP2 in 293 cells.
293/EBP2-DBD cells were transfected with an expression plasmid for FLAG-EBP2, and interphase cells were visualized by using antibodies against
the DBD (FITC) or FLAG-EBP2 (rhodamine). EBP2-DBD and FLAG-EBP are largely localized to regions of the nucleus that stain poorly with
DAPI (compare panel DAPI to panels DAPIEBP-DBD and DAPIFLAG-EBP2). Also, EBP2-DBD localizes similarly to EBP2 within cells
(compare panel DAPIEBP2-DBD to panels DAPIFLAG-EBP2 and MERGE).
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cemid (0.1 g/ml) and prepared for whole-cell immunofluo-
rescence by using an antibody against the EBNA1 DBD. Im-
ages were deconvolved and are shown with the condensed
chromatin in focus (Fig. 8A). As can be seen in the images of
multiple cells, there is no overlap between EBP2-DBD and
condensed chromatin in the same geometric plane. This is
indicated by the almost perfect exclusion of the FITC (EBP2-
DBD) signal from anywhere the DAPI signal is present. This
indicates that EBP2-DBD does not bind condensed chromatin
within intact cells.
We next examined whether endogenous EBP2 was localized
to metaphase chromosomes in cells that expressed EBNA1
(Fig. 8B). For this, metaphase spreads were prepared from
293/EBNA1 cells stalled in early metaphase with Colcemid,
followed by indirect immunofluorescence against both EBNA1
(rhodamine) and EBP2 (FITC). Because the FITC channel of
our camera is more sensitive than the rhodamine channel, we
decided to detect EBNA1 by using a rhodamine-conjugated
secondary antibody (red) and EBP2 with an FITC-conjugated
secondary antibody (green) for this analysis. As observed pre-
viously, EBNA1 stained metaphase chromosomes as discrete
punctate dots, which overlapped greatly with the Hoechst-
stained metaphase chromosomes (48). In stark contrast, de-
spite our ability to readily stain EBP2 in the nucleoli of inter-
phase cells (Fig. 6), we failed to observe any signal on isolated
metaphase chromosomes (Fig. 8B). This result is inconsistent
with those obtained with a GFP-EBP2 fusion (26) but is con-
sistent with those reported previously for native EBP2 in HeLa
cells (10). Possible reasons for the inconsistency are discussed
below. We also observed that EBP2 failed to stain metaphase
chromosomes prepared from 293 cells (data not shown).
We were concerned that our localization studies were per-
formed with the same monoclonal antibody as those per-
formed previously (10), although this antibody does work to
detect EBP2 in nucleoli (Fig. 6) (10). To eliminate the possi-
bility that this monoclonal antibody does not detect EBP2
bound to metaphase chromosomes, we transfected FLAG-
EBP2 into 293/EBNA1 cells, isolated metaphase chromo-
somes, and proceeded to detect EBNA1 and FLAG-EBP2 by
indirect immunofluorescence (Fig. 8C), with rabbit polyclonal
antibodies to EBNA1 and a monoclonal anti-FLAG antibody.
We failed to observe any association between EBP2 and meta-
phase chromosomes, although the association of EBNA1 with
such chromosomes was clearly evident (Fig. 8C).
EBP2 is crucial for the formation of ribosomes in yeast, and
it is likely to have that same function in mammalian cells. As
such it has to be partitioned into both daughter cells, or one
daughter will not survive. We were concerned that the methods
we used to stall cells in mitosis, drop swollen cells on slides, or
fix chromosomes masked prevented the detection of EBP2. To
test this possibility, we examined the localization of EBNA1
and EBP2 in 293/EBNA1 cells obtained by mitotic shake-off
without any drug treatment. For this purpose, we grew 	108
cells and recovered ca. 107 cells in various stages of mitosis.
Such intact cells were fixed onto coverslips and then processed
for indirect immunofluorescence with antibodies to EBNA1
and EBP2. An example of a cell in early metaphase is shown in
Fig. 8D. We observed that although EBNA1 was distributed
throughout the cell and is not especially concentrated on the
condensed DNA, most of the EBP2 was on the periphery
directed away from the condensed DNA. An example of a cell
in late anaphase is shown in Fig. 8E. Here it can be seen that
most, but not all, of the EBNA1 staining coincides with the
condensed DNA. The EBP2 signal is about equivalent in what
will become the two daughter cells but is not associated with
DNA. In our examination of more than 200 such mitotic cells,
we did not find any cells in which EBP2 was associated with
mitotic DNA. However, it is very likely that EBP2 is parti-
tioned equally. Examining the FITC signal with softWoRx
indicates that it is often approximately equal in the two daugh-
ters just prior to cytokinesis. Our studies on such intact cells
also indicated that EBNA1 and EBP2 do often colocalize, but
when they colocalize it is not on condensed chromosomes.
In summary, we observed that EBP2 and EBP2-DBD are
localized to nucleoli. We observe that neither protein associ-
ates with metaphase chromosomes, either in intact cells (Fig.
8A, D, and E) or in metaphase spreads (Fig. 8B and C).
Consistent with this, EBP2-DBD fails to support the robust
FIG. 7. EBP2-DBD does not support the replication of oriP plas-
mids in human cells. (A) An oriP replication reporter plasmid (i.e.,
plasmid 1033) was transfected into 293/EBNA1 and 293/EBP2-DBD
cells, after which cells were propagated in the absence of selection and
harvested 4 or 21 days posttransfection. The transfected cell line is
indicated above each lane, and the time point is given above each set
of lanes. DNAs were extracted and digested with DpnI, linearized with
XbaI, and quantified by Southern analysis with a probe generated from
plasmid 1033 digested with HincII. The amounts of standards loaded
are indicated above each lane, and their electrophoretic mobilities are
indicated by “A.” “B” indicates the electrophoretic mobility of the
linearized replicated plasmid 1033. Quantified results from two repe-
titions of this experiment are given in Table 3.
TABLE 3. Average copy number of DpnI-resistant oriP replication
reporter plasmid (i.e., plasmid 1033) at 4 and 21 days
posttransfection in 293 cells expressing EBP2-DBD or EBNA1
Days
posttransfection
Cell line transfecteda (mean copy no.  SD)
293/EBNA1 293/EBP2-DBD
4 32  13 2  2
21 23  5 
0.5
a Data represent the means and standard deviations of two experiments. Copy
numbers are corrected for transfection efficiency. The average transfection effi-
ciency was 81%, as determined by flow cytometry for a cotransfected GFP
expression plasmid.
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replication of an oriP plasmid, in contrast to HMGA1a-DBD,
a protein that does bind metaphase chromosomes (48) and
whose staining on such chromosomes closely resembles that of
EBNA1 (Fig. 9A).
DISCUSSION
The latent genome of EBV is stably maintained as an epi-
some within cells, a process that requires the viral protein
EBNA1. EBNA1 maintains EBV genomes or oriP plasmids in
proliferating cells by tethering them to host chromosomes. The
genome or oriP maintenance activity of EBNA1 requires the
amino-terminal domain of EBNA1 that is known to associ-
ate with chromatin. This association requires two positively
charged regions within the amino terminus that termed “A”
(aa 33 to 89) and “B” (aa 328 to 378). Region B associates with
a cellular nucleolar protein (p40), originally cloned by Busch
and coworkers (10), and reisolated as an EBNA1-interacting
protein and termed EBP2 (50). In genetic experiments, it has
been shown that expression of human EBP2 permits budding
yeast that express EBNA1 to retain yeast ARS/FR plasmids
through multiple cell cycles (27), although partitioning was not
directly addressed. Using flat-field indirect immunofluores-
cence microscopy, an association between a GFP-EBP2 fusion
with human metaphase chromosomes has been observed at a
630 resolution (26). On this basis it has been proposed that
EBP2 mediates EBNA1’s association with metaphase chromo-
somes. These studies intrigued us for several reasons. First,
EBP2 associated exclusively with domain B of EBNA1, but not
with domain A, whereas studies by others suggested that
EBNA1 derivatives lacking either domain B or domain A were
equivalent in function (34). Second, the localization of GFP-
EBP2 (26) differs from that originally observed (10) and also
differs from that reported for the yeast homolog of EBP2 (54).
Third, our own studies examining the localization of EBNA1
on metaphase chromosomes indicated that it is bound in a
punctate manner at discrete locations (Fig. 4, 8, and 9) (48)
and does not uniformly coat chromosomes as reported for
GFP-EBP2 (26). Finally, studies by Marechal et al. with fu-
sions of domain A and domain B with GFP indicated that each
could associate with metaphase chromosomes in a punctate
manner (37), a result we interpreted to indicate minimally that
EBNA1 has EBP2-dependent and -independent modes of
chromosome association.
Recent work by us and others has elucidated the require-
ments of metaphase chromosome association for the replica-
tion and partitioning functions of EBNA1 (24, 48). In both
studies, the entire amino terminus of EBNA1 (both domains A
and B) was replaced with cellular proteins that associate with
metaphase chromosomes, histone H1 and HMGA1a (24, 48).
Both of these fusion proteins support the long-term replication
of oriP plasmids. For one of these proteins, HMGA1a-DBD,
we have determined that its activity in the replication of oriP
plasmids is indistinguishable from wild-type EBNA1 (48). In
addition, the rate of loss for oriP plasmids in human cell lines
that express the HMGA1a-DBD protein is mathematically in-
distinguishable from the rate of loss of the same plasmids in
matched cell lines that express wild-type EBNA1. This obser-
vation suggested to us that the amino terminus of EBNA1 and
HMGA1a acted via similar molecular mechanisms. A corollary
to this argument implies that this molecular mechanism is also
shared by histone H1. One property that histone H1 and
HMGA1a share with EBNA1 is that they associate with meta-
phase chromosomes. It appeared unlikely to us that this prop-
erty alone explained the ability of EBNA1 to support the stable
replication and partitioning of oriP plasmids because a fusion
between histone H3 and the DBD of EBNA1 does associate
with metaphase chromosomes but does not support the tran-
sient or stable replication of oriP plasmids (A. Balasubrama-
niam and A. Aiyar, unpublished results). Detailed studies on
the association of histone H1 and HMGA1a with metaphase
chromosomes indicate that these two proteins share another
property. Both proteins bind AT-rich sequences with high af-
finity, although the protein motifs are different (16, 17, 25, 38,
46): histone H1 through a motif that is now called the histone
H1-fold and HMGA1a through a motif called the AT hook
(43). Using giant chromosomes from Drosophila, or the Indian
muntjac, Laemmli and coworkers have demonstrated that
metaphase chromosomes are not uniformly condensed (41,
46). Rather, these chromosomes consist of highly condensed
regions (Q bands) connected by AT-rich R bands that are not
condensed (20, 45, 46). These AT-rich R bands have been
termed by Laemmli as SARs. How does this relate to the
distribution of histone H1 or HMGA1a on metaphase chro-
mosomes? The groups of Reeves and Laemmli have together
shown that HMGA1a and histone H1 are largely or entirely
localized to these SARs on metaphase chromosomes (25, 46,
52, 63), such that they stain in a highly punctate manner (16,
25, 46) that is indistinguishable from the punctate staining of
EBNA1 on metaphase chromosomes. That histone H1 and
HMGA1a have a high affinity for the same regions on chro-
mosomes is also indicated by studies demonstrating that
HMGA1a can compete with histone H1 for binding to SARs in
vitro (63). Thus far, the only cellular proteins that have func-
tionally replaced the amino terminus of EBNA1 (24, 48) pref-
erentially associate with AT-rich DNA and are localized to
SARs on metaphase chromosomes.
We therefore sought to determine whether the amino ter-
minus of EBNA1 preferentially associated with AT-rich DNA
and if this association correlated with the stable replication of
oriP plasmids. Sequence analysis indicated that domains A and
B of EBNA1 shared the GR repeats found in many AT hook
proteins (4), including HMGA1a. Other members of this fam-
ily, such as ARBD or MBD2a, have much longer GR repeats,
such as those found in EBNA1. Our experiments indicated that
both domains have a high affinity for AT-rich DNA. Further,
the binding is displaced by the minor groove binding drugs
distamycin and netropsin (data not shown), indicating that the
association occurs via interactions in the minor groove, as it
does for HMGA1a. Full-length EBNA1 (that lacks the Gly-Ala
repeats) expressed in baculovirus also had AT hook activity
comparable to purified domains A and B or peptides contain-
ing the AT hook region.
Because both domains A and B had AT hook function, but
only domain B associated with EBP2, we could test whether
the association of EBNA1 with metaphase chromosomes, and
its ability to support the transient and stable replication of
oriP-plasmids better correlated with AT hook function or an
association with EBP2. For this we constructed versions of
EBNA1 that had one or more copies of domain A (but lacked
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domain B) or a derivative of EBNA1 in which the entire amino
terminus was replaced with EBP2. Our studies clearly indicate
that any version of EBNA1 that contains at least two copies of
domain A supports stable replication of wild-type oriP (which
has 20 binding sites for EBNA1 in FR). Curiously, a derivative
with just a single copy of domain A also supports the stable
replication of oriP plasmids that contain 30 EBNA1 binding
sites in FR. This result leads us to hypothesize that the teth-
ering of EBV episomes with metaphase chromosomes is de-
pendent upon two associations: the first is between the amino
terminus of EBNA1 and the chromosome, and the second is
between the carboxy terminus of EBNA1 and the EBV epi-
some. The former is modulated by the number of copies of
domain A (and presumably domain B) in EBNA1, and the
latter is modulated by the number of EBNA1-binding sites on
the EBV episome. Although 1A-DBD presumably associates
with chromosomes less well and therefore does not stably rep-
licate a wild-type oriP-plasmid, increasing the number of bind-
ing sites in FR from 20 to 30 provides additional A domains
that can tether the plasmid to chromosomes, rescuing the de-
fect. Put more simply, increasing the amount of 1A-DBD on
the episome increases the avidity of the plasmid-protein com-
plex for chromosomes without changing the affinity of each
1A-DBD for chromatin per se. Our results with 1A-DBD
closely parallel those of Mackey and Sugden, who observed
that this protein was approximately half as functional as wild-
type EBNA1 and equivalent in function to 1B-DBD (34).
Our results with the EBP2-DBD fusion are intriguing. This
FIG. 8. EBP2-DBD and EBP2 do not associate with condensed mitotic chromatin within cells or with isolated metaphase chromosomes.
(A) 293/EBP2-DBD cells were treated with Colcemid and subjected to whole-cell immunofluorescence with the K67.3 antibody to the DBD of
EBNA1. In these images, the cells are mitotic, the nuclear envelope has broken down, but the cell membrane is intact. EBP2-DBD is visualized
with a FITC-conjugated secondary antibody, whereas condensed mitotic chromatin is counterstained with DAPI. The upper row shows decon-
volved images from three cells visualized with a 100 objective lens, indicating that EBP2-DBD stains wherever mitotic chromatin is absent. The
lower row shows a single cell also taken with a 100 objective lens, but with 1.5 optical enhancement from an independent experiment, also
indicating an exclusion of EBP2-DBD from condensed mitotic chromatin within intact cells, although the protein can be detected readily within
such cells. (B) Endogenous EBP2 is not bound to metaphase chromosomes isolated from 293/EBNA1 cells. Metaphase spreads were recovered
from 293/EBNA1 cells and subjected to coimmunofluorescence with K67.3 (rhodamine-conjugated secondary antibody) and a monoclonal
antibody against endogenous human EBP2 (FITC-conjugated secondary antibody). As previously observed (48), EBNA1 (red) coats metaphase
chromosomes in a distinct, punctate manner; EBP2 (green) is not found on the isolated metaphase chromosomes. (C) Overexpressed FLAG-EBP2
is not bound to isolated metaphase chromosomes. Metaphase spreads were recovered from 293/EBNA1 cells transiently transfected with a
FLAG-EBP2 expression plasmid and subjected to coimmunofluorescence as in panel B. EBNA1 was detected and visualized as described above,
whereas FLAG-EBP2 was detected by using a monoclonal anti-FLAG antibody (Chemicon) and visualized by using an FITC-conjugated secondary
antibody. Even when overexpressed, EBP2 was not detected on metaphase chromosomes. (D) Localization of EBP2 and EBNA1 within a cell in
early metaphase isolated by mitotic shake-off. 293/EBNA1 cells in mitosis were isolated by shake-off, fixed on slides, and stained with a monoclonal
antibody against endogenous EBP2, followed by an FITC-conjugated secondary antibody, and the K67.3 rabbit polyclonal antibody against EBNA1
(rhodamine-conjugated secondary). (E) Localization of EBP2 and EBNA1 within a cell in late anaphase. 293/EBNA1 cells were isolated and
processed as in panel D.
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fusion localizes precisely as wild-type EBP2 in cells. It is pri-
marily nucleolar, and we did not find any association of either
protein with metaphase chromosomes similar to the original
observations (10). We have examined the localization of EBP2
within cells obtained by mitotic shake-off, and these results
confirm our observations that it does not associate with con-
densed chromosomes. There are two differences in the meth-
ods used by us and those used by others (26, 58). We used
deconvolution or confocal microscopy instead of flat-field mi-
croscopy and higher-powered objectives (100 and 150).
That we failed to observe EBP2 localized to metaphase chro-
mosomes is underscored by the inability of the EBP2-DBD
fusion protein to support the transient or stable replication of
oriP plasmids and that this protein, which is localized to nu-
cleoli, acts as a potent dominant-negative of wild-type EBNA1.
This result is similar to what we have demonstrated previously
with another protein (HMG1-DBD) (48). These results are
consistent with our previous hypothesis that nuclear localiza-
tion by itself is not sufficient for the transient replication of oriP
plasmids; rather, metaphase chromosome localization is re-
quired for both transient and stable replication of these epi-
somes (48).
How do we reconcile our observation that EBP2 does not
colocalize with EBNA1 to metaphase chromosomes with ge-
netic data that expression of human EBP2 increases the reten-
tion of ARS/FR plasmids in budding yeast? There are at least
two possibilities. The simplest explanation is that, although AT
hook proteins such as HMGA1a, bind SARs on metaphase
chromosomes, it is possible that their binding is mediated by a
“loading protein” that doesn’t remain a part of the bound
complex. EBP2 may function as such a loader for EBNA1. If it
does, there have to be other such loaders as well, because
derivatives of EBNA1 that lack domain B continue to bind
metaphase chromosomes and stably replicate oriP plasmids.
Another possible explanation for the genetic observations in
budding yeast may lie in the fundamental differences in mitosis
FIG. 9. Model for the partitioning of oriP plasmids on a per-replicon basis. (A) High-resolution indirect immunofluorescence comparing the
localization of wild-type EBNA1 and HMGA1a-DBD on metaphase chromosomes by using an antibody to the DBD of EBNA1. The localizations
of both proteins were similar; many pairs of sister chromatids contained an equal number of dots for both proteins. In several instances, the dots
were symmetrically positioned on both sister chromatids. (B) Model of a portion of a chromosome based on the models constructed by Laemmli
and coworkers (20, 45, 46). For convenience we have depicted a metaphase chromosome with Q and R bands containing AT-rich SARs. Laemmli
and coworkers have demonstrated that sequences present as SARs on interphase chromosomes are present in R bands in metaphase chromosomes
(45, 46). We propose that EBNA1 or HMGA1a-DBD tethers oriP plasmids to SARs that are present relatively infrequently compared to other
sequences on chromosomes. Upon S phase, when there is replication of chromosomes, we hypothesize that the replicated oriP plasmids are
partitioned between the sister SARs on sister chromatids, by a distribution of EBNA1 or HMGA1a-DBD to each sister SAR. Key to this model
is that the actual partitioning event is concomitant with replication and occurs during S phase. The plasmids remain tethered to sister chromatids
and piggyback on the sisters during mitosis (9).
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between budding yeast and human cells. The nuclear envelope
is not dissolved in budding yeast during mitosis, and there is
typically a single large nucleolus that occupies about half the
nucleus (62). The contents of this large nucleolus are retained
within the nucleus during mitosis (on account of the nuclear
membrane not dissolving during mitosis). Therefore, a com-
plex of EBP2 and EBNA1 may permit the efficient retention of
ARS/FR plasmids within this large nucleolus during inter-
phase, and the random retention of its contents during mitosis.
Such retention and distribution of ARS plasmids is not hith-
erto unknown. ARS plasmids with Sir4p binding sites are re-
tained more efficiently than plasmids with an ARS alone (3),
although Sir4 does not function in the partitioning of chromo-
somes. It should also be noted that although ARS plasmids
containing Sir4 sites are retained more efficiently in budding
cells, they are not partitioned equally when tested by partition-
ing assays (3, 22, 30).
The observation that the amino terminus of EBNA1 has AT
hooks probably has implications for both the replication and
partitioning of EBV episomes. It is clear that the replication of
these episomes is ORC dependent, although the mechanism by
which ORC is loaded onto oriP remains enigmatic (15, 47).
Kelly and coworkers have recently purified human ORC and
tested its DNA-binding specificity. Although this complex lacks
AT hooks that the ORC from S. pombe has (12, 32), it still
associates preferentially with AT-rich DNA when tested with
synthetic substrates and in an assay identical to the one we
used (55). We believe that an association between EBNA1 and
ORC may be first mediated by their common localization to
AT-rich DNA within cells, such as SARs. This suggestion ex-
plains two observations. The first is that the DBD alone of
EBNA1 does not support even the transient replication of oriP
plasmids (28). The second is that fusing proteins that bind
AT-rich DNA, such as histone H1 or HMGA1a, to the DBD of
EBNA1 restores the replication of oriP plasmids (24, 48).
Are EBV episomes partitioned equally and how might the
AT hooks of EBNA1 contribute to this process? In studies
conducted 15 years ago, Sugden and Warren monitored the
loss of Hygr and G418r oriP plasmids present at different copy
numbers in the same cell and found that both the selected and
the unselected plasmids were lost at the same rate (53). When
these data are analyzed by using mathematical models created
to understand the partitioning of plasmids (42), it best fits a
model in which plasmids are largely, if not entirely, partitioned
equally on a per-replicon basis. Random partitioning of a plas-
mid pool would have resulted in the low-copy unselected plas-
mid being diluted out very rapidly (within five to eight pas-
sages) by the high-copy selected plasmid. Equal partitioning
also fits the observations of Delecluse et al., who observed by
fluorescence in situ hybridization analysis that episomal EBV
often appeared as a pair of dots on paired sister chromatids in
metaphase spreads (14). How might the AT hooks of EBNA1
facilitate an equal partitioning event that occurs for each rep-
licon? Although we have no direct evidence that EBNA1 as-
sociates with SARs on metaphase chromosomes as HMGA1a
does, the distribution of EBNA1 and HMGA1a-DBD on
metaphase chromosomes cannot be distinguished, and the
maintenance of oriP plasmids by these two proteins is mathe-
matically identical. If EBNA1 were to localize to a SAR on an
interphase chromosome, it is possible that after S phase,
EBNA1, along with the replicated daughter oriP plasmid, is
distributed to the sister SAR on the sister chromatid. The
indirect immunofluorescence analysis of some of our meta-
phase spreads indicates that the distribution of EBNA1 “dots”
on some sister chromatids is approximately equal, an observa-
tion that is also true for HMGA1a-DBD (see Fig. 9A). In this
model that is presented schematically in Fig. 9B, the per-
replicon partitioning event is simply the distribution of EBNA1
to the sister SAR on the newly replicated sister chromatid.
Replication of DNA may be sufficient to very transiently dis-
place EBNA1 bound to a SAR and permit reassociation with
SARs on both sister chromatids. However, there is at least one
other possibility. The Saccharomyces cerevisiae 2m plasmids
in budding yeast are partitioned on a per replicon basis via a
counting event that involves cohesin cleavage, although these
plasmids are not centromeric (40). On human chromosomes
cohesins are now known to be loaded via the NuRD complex
(19), which has a high affinity for AT-rich sequences (59). It is
possible that cohesins are loaded onto oriP plasmids by virtue
of EBNA1 and the NuRD complex being colocalized to AT-
rich sequences and that the actual per-replicon partitioning
event requires cohesin cleavage, much as occurs for 2m plas-
mids.
Our results that EBNA1 associates with chromosomes via
AT hooks may also have implications for the replication and
partitioning of Kaposi’s sarcoma herpesvirus. Kaye and co-
workers have demonstrated that the N terminus of LANA is
essential for the stable replication of KSHV episomes (6).
Krithivas et al. have shown that this region of LANA associates
with MeCP2 (also called MBD2a) (31). In addition to binding
methyl CpG, MeCP2/MBD2a is an AT hook protein that is
known to associate with SARs (4, 13, 56). Further, expression
of MeCP2 in mouse cells facilitates the association of LANA
with chromosomes in mouse cells, suggesting that LANA as-
sociates with chromosomes indirectly but through an AT hook-
mediated tether (31). Finally, similar to EBNA1, the N termi-
nus of LANA can be replaced with histone H1 but not with
cellular DNA-binding proteins that associate with metaphase
chromosomes but do not preferentially associate with AT-rich
sequences, such as histone H2b (49).
In summary, we have determined that the amino terminus of
EBNA1 has two regions that have AT hook activity. We have
demonstrated this activity strongly correlates with the ability of
EBNA1 to associate with metaphase chromosomes and to
support the replication and partitioning of oriP plasmids.
Our results provide a molecular mechanism that explains how
EBNA1 tethers EBV genomes to cellular chromosomes, a
process that is essential for the replication and partitioning of
viral genomes in cells latently infected by EBV.
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